Perioperative levosimendan in cardiac surgery: A systematic review with meta-analysis and trial sequential analysis. (15th January 2018)

• Record Type: Journal Article
• Authors: Putzu, Alessandro; Clivio, Sara; Belletti, Alessandro; Cassina, Tiziano
• Is Part Of: International journal of cardiology. Volume 251(2018)
• Page Start: 22
• Page End: 31
• Publication Date: 2018-01-15
• Subjects: Levosimendan -- Cardiology -- Cardiac surgery -- Mortality -- Systematic review -- Meta-analysis; Cardiology -- Periodicals; Electronic journals; 616.12
• DOI: 10.1016/j.ijcard.2017.10.077
• Languages: English
• ISSNs: 0167-5273

Abstract

Abstract: Background: Several studies suggested beneficial effects of perioperative levosimendan on postoperative outcome after cardiac surgery. However, three large randomized controlled trials (RCTs) have been recently published and presented neutral results. We performed a systematic review with meta-analysis and trial sequential analysis (TSA) to assess benefits and harms of perioperative levosimendan therapy in cardiac surgery. Methods: Electronic databases were searched up to September 2017 for RCTs on preoperative levosimendan versus any type of control. The Cochrane methodology was employed. We calculated odds ratio (OR) or Risk Ratio (OR) and 95% confidence interval (CI) using fixed-effects meta-analyses and we further performed TSA. Results: We included data from 40 RCTs and 4246 patients. Pooled analysis of 5 low risk of bias trials (1910 patients) showed no association between levosimendan and mortality (OR 0.86 [95% CI, 0.62, 1.18], p = 0.34, TSA inconclusive), acute kidney injury, need of renal replacement therapy, myocardial infarction, ventricular arrhythmias, and serious adverse events, but an association with higher incidence of supraventricular arrhythmias (RR 1.11 [95% CI, 1.00, 1.24], p = 0.05, TSA inconclusive) and hypotension (RR 1.15 [95% CI, 1.01, 1.30], p = 0.04, TSA inconclusive). Analysis including all 40 trials found that levosimendan was associated with lower postoperative mortality (OR 0.56 [95% CI, 0.44, 0.71], p < 0.00001, TSA conclusive), acute kidney injury, and renal replacement therapy, and higher incidence of hypotension. Conclusions: There is not enough high-quality evidence to neither support nor discourage the systematic use of levosimendan in cardiac surgery.